This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Robert R. Fenichel, PhD, MD; Raymond J. Lipicky, MD
Rockville, Md

Arch Intern Med. 1995;155(1):117.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Our editorial¹ in the July 11, 1994, issue of the ARCHIVES stated that betaxolol-chlorthalidone and bisoprolol-hydrochlorothiazide are the only fixed-dose combination products approved in the United States as first-line pharmacotherapy for hypertension. This is incorrect.

We inadvertently neglected to discuss the fixed-dose combination of captopril and hydrochlorothiazide. This combination was approved in 1984, and it was approved as first-line therapy in 1991. The latter approval was a consequence of the marked improvement in the regimen that the combination allows, ie, the combination can be effectively administered once a day, while captopril monotherapy must be given twice or three times a day. The approval of captopril-hydrochlorothiazide as first-line therapy was, thus, an exception to the generalization overbroadly stated in our editorial that no combination of an angiotensin-converting enzyme inhibitor and hydrochlorothiazide could ever be approved as first-line therapy. Captopril-hydrochlorothiazide was approved—and similar decisions might be made in the future—because the . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?